February 5, 2025 - 04:36

A recent study sheds light on the reasons behind the significant number of individuals who discontinue the use of GLP-1 medications for weight loss and diabetes management within a year. Key factors influencing this trend include the high costs associated with these drugs, which can be a substantial burden for many patients. Additionally, reported side effects, such as gastrointestinal issues and nausea, contribute to the decision to stop treatment.
As these medications gain popularity for their effectiveness, the industry is also witnessing shifts in focus. Notably, Noom has announced staff reductions as it pivots towards prioritizing GLP-1 products. This strategic move highlights the growing emphasis on these medications in the weight loss and diabetes sectors.
The study's findings raise important questions about patient support and education, suggesting that addressing financial and health-related concerns could improve adherence to these treatments. Understanding these dynamics is crucial for healthcare providers aiming to enhance patient outcomes in managing weight and diabetes.
February 21, 2026 - 09:17
I spent 22 years unable to burp. Here’s what happened when I finally could.For decades, a silent and often misunderstood condition governed daily life. Known informally as `no-burp syndrome,` or retrograde cricopharyngeus dysfunction (R-CPD), it leaves sufferers...
February 20, 2026 - 21:10
USF Health Morsani College of Medicine claims two national Top 10 rankings in NIH fundingThe University of South Florida Health Morsani College of Medicine has demonstrated significant research strength, earning two coveted spots in the national Top 10 for National Institutes of Health...
February 20, 2026 - 08:41
Cambridge mental health charity says £205K grant is 'pivotal'A Cambridge-based mental health charity has described a substantial new grant as `pivotal` to its future, enabling a significant expansion of its community services. The organization, Sew Positive,...
February 19, 2026 - 19:15
Svetlana Lipyanskaya, MPA, FACHE to be Appointed CEO of Maimonides Health, Pending Final Approval of Partnership with NYC Health + Hospitals - NYC Health + HospitalsNew York, NY — Svetlana Lipyanskaya, MPA, FACHE, is set to become the new Chief Executive Officer of Maimonides Health, pending final approval of a new partnership between the Brooklyn-based...